75+ Active Companies working to develop 75+ Pipeline Therapies for Plaque psoriasis Treatment Landscape | Major Companies- Bristol-Myers Squibb, Meiji Pharma, and others

DelveInsight's, "Plaque Psoriasis Pipeline Insight 2023" report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in Plaque Psoriasis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

In the Plaque Psoriasis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Plaque Psoriasis NDA approvals (if any), and product development activities comprising the technology, Plaque Psoriasis collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Key Takeaways from the Plaque Psoriasis Pipeline Report

• DelveInsight's plaque psoriasis pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for plaque psoriasis treatment.

• Leading plaque psoriasis companies include Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics, Biocon, and others are evaluating novel plaque psoriasis treatment drugs candidate to improve the treatment landscape.

• Promising plaque psoriasis pipeline therapies include ARQ-151, ABY-035, AK101, DMB-3115, DLX105-DMP, Deucravacitinib, BAT2306, JNJ-77242113, ME3183, ADX-629, ABP 654, GLPG3667, FYB202, CF101, TLL018, NDI-034858, SCD-044, SHR-1314, Bmab1200, PF-07038124, ONO-4685, CT303, Jaktinib, AUR101, CT-P43, Hemay005, IBI112, SCT630, AT193, and others.

• The Plaque Psoriasis companies and academics that are working to assess challenges and seek opportunities that could influence Plaque Psoriasis R&D. The Plaque Psoriasis pipeline therapies under development are focused on novel approaches to treat/improve the disease condition.

Request a sample and discover the recent advances in Plaque Psoriasis Drug Treatment @ Plaque Psoriasis Pipeline Report- https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Plaque Psoriasis Overview
Psoriasis is recognized as the most prevalent immune-mediated inflammatory disease, involving skin and joints and associated with abnormalities of other systems. Plaque psoriasis is the commonest clinical type of psoriasis. Even though the condition is not life-threatening, it is difficult to treat and response rates vary widely.

Recent Developmental Activities in the Plaque Psoriasis Treatment Landscape

• In May 2022, Bristol Myers Squibb announced two-year results from the POETYK PSO long-term extension (LTE) trial demonstrating durable efficacy and a consistent safety profile with deucravacitinib treatment in adult patients with moderate to severe plaque psoriasis. Clinical efficacy was maintained through up to two years of deucravacitinib treatment, with response rates at Week 60 in the LTE of 77.7% and 58.7% for Psoriasis Area and Severity Index (PASI) 75 and static Physicians Global Assessment (sPGA) 0/1 (clear/almost clear skin), respectively.

• In April 2022, Amgen announced preliminary results from a Phase 3 study evaluating the efficacy and safety of ABP 654 compared to STELARA® (ustekinumab) in adult patients with moderate to severe plaque psoriasis. The study met the primary efficacy endpoint, demonstrating no clinically meaningful differences between ABP 654 and STELARA.

• In March 2022, Arcutis Biotherapeutics announced new pooled results from the DERMIS Phase III trials of roflumilast cream are available in four abstracts at the 2022 American Academy of Dermatology annual meeting, that took place in Boston, MA. Roflumilast is a selective and highly potent phosphodiesterase-4 inhibitor (PDE4) being investigated by Arcutis as a non-steroidal topical treatment for multiple inflammatory skin diseases, including plaque psoriasis.

• In March 2022, Can-Fite BioPharma Ltd. announced that top line data from its Phase III Comfort™ study of Piclidenoson in the treatment of moderate-to-severe plaque psoriasis are scheduled to be released in Q2 2022 due to an unanticipated delay in the collection of study data. The study enrolled more than 400 patients across 30 sites in Europe, Israel, and Canada.

• In May 2022, Nimbus Therapeutics announced the presentation of new data from multiple Phase 1 clinical studies of its investigational oral allosteric tyrosine kinase 2 (TYK2) inhibitor, NDI-034858, in both healthy volunteers and patients with moderate-to-severe psoriasis.Phase 2b clinical studies to evaluate NDI-034858 in moderate-to-severe plaque psoriasis (NCT04999839) and active psoriatic arthritis (NCT05153148) are ongoing.

• In December 2021, Arcutis Biotherapeutics, Inc. announced the U.S. Food and Drug Administration's (FDA) acceptance for review of the company's new drug application (NDA) for roflumilast cream for the treatment of psoriasis in adults and adolescents. The FDA assigned the application a Prescription Drug User Fee Act (PDUFA) target action date of July 29, 2022.

• In May 2021, Meiji Seika Pharma Co., Ltd. announced that the bioequivalence of DMB-3115, a prposed ustekinumab biosimilar, had been demonstrated in phase I clinical trial compared to the refrence products marketed in Europe and the United States. Meiji also announced the initiation of a phase III multi-regional clinical trial in patients with plaque psoriasis. Those clinical trials are conducted in collaboration with Dong-A Socio Holdings.

Find out more information of the latest Drugs Launch, News, and Breakthroughs of the Plaque Psoriasis Pipeline Report @ Latest Plaque Psoriasis Drugs Launch- https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Plaque Psoriasis Emerging Drugs Profile

• ARQ-151: Arcutis Biotherapeutics
Topical roflumilast cream (ARQ-151) is a small molecule inhibitor of phosphodiesterase-4 (PDE4), an intracellular enzyme that increases the production of proinflammatory mediators and decreases the production of anti-inflammatory mediators, and has been implicated in a wide range of inflammatory diseases including psoriasis, eczema, and chronic obstructive pulmonary disease (COPD). PDE4 is an established target in dermatology, and other PDE4 inhibitors have been approved by the FDA for the systemic treatment of plaque psoriasis and the topical treatment of atopic dermatitis. Topical roflumilast cream is a highly potent, selective PDE4 inhibitor in a convenient, once-daily formulation that Arcutis is developing for chronic plaque psoriasis and atopic dermatitis.

• ABY-035: Affibody
ABY-035 is a novel bispecific agent, potently targeting both subunits of IL-17A as well as albumin. ABY-035 has been specifically designed to utilize the strengths of Affibody's technology platform to create a very small protein drug (18 kDa, an eighth of the size of an antibody) with very high apparent affinity to IL-17A (KD ~300fM) and antibody-like half-life due to the strong (KD ~50pM) binding affinity to serum albumin.

• AK101: Akeso Biopharma
AK101 injection is a novel antibody drug developed independently by the Company under the National Major Innovative Drug Projects. It is intended to be used for the treatment of autoimmune diseases such as psoriasis, Crohn's disease, ulcerative colitis and lupus. AK101 clinically treats autoimmune diseases by blocking the biological activities of cytokines IL-12 and IL-23. Johnson & Johnson's Ustekinumab (trade name: Stelara) which has the same drug targets has been approved by the FDA for the treatment of psoriasis, Crohn's disease, and ulcerative colitis, and yielded US$6.4 billion in sales in 2019. Currently, it is in Phase III stage of clinical trial evaluation to treat Plaque Psoriasis.

Plaque Psoriasis Therapeutics Assessment
The plaque psoriasis pipeline report proffers an integral view of the plaque psoriasis emerging novel therapies segmented by Stage, Product Type, Molecule Type, Mechanism of Action, and Route of Administration.

Learn more about the emerging Plaque Psoriasis pipeline therapies @ Plaque Psoriasis Ongoing Clinical Trials Analysis- https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Plaque Psoriasis Pipeline Report

• Coverage: Global

• Plaque Psoriasis Companies: Arcutis Biotherapeutics, Affibody, Akeso Biopharma, Dong-A ST Co., Ltd., DelArrivo, Inc., Bristol-Myers Squibb, Bio-Thera Solutions, Janssen Research & Development, LLC, Meiji Pharma USA Inc., Aldeyra Therapeutics, Inc., Amgen, Bioeq GmbH, Can-Fite Biopharma, Hangzhou Highlightll Pharmaceutical Co., Ltd, Nimbus Therapeutics, Sun Pharmaceutical Industries, Jiangsu Hengrui Medicine, Ono Pharmaceutical, GC Cell Corporation, Suzhou Zelgen Biopharmaceuticals, Aurigene Discovery Technologies Limited, Celltrion, Tianjin Hemay Pharmaceutical Co., Ltd, Innovent Biologics (Suzhou) Co. Ltd., Sinocelltech, Azora Therapeutics, Biocon, and others

• Plaque Psoriasis Pipeline Therapies: ARQ-151, ABY-035, AK101, DMB-3115, DLX105-DMP, Deucravacitinib, BAT2306, JNJ-77242113, ME3183, ADX-629, ABP 654, GLPG3667, FYB202, CF101, TLL018, NDI-034858, SCD-044, SHR-1314, Bmab1200, PF-07038124, ONO-4685, CT303, Jaktinib, AUR101, CT-P43, Hemay005, IBI112, SCT630, AT193, and others.

• Plaque Psoriasis Pipeline Segmentation: Product Type, Molecule Type, Route of Administration

Dive deep into rich insights for drugs for Plaque Psoriasis Market Drivers and Plaque Psoriasis Market Barriers, click here @ Plaque Psoriasis Unmet Needs and Analyst Views- https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of content
1. Introduction
2. Executive Summary
3. Plaque Psoriasis: Overview
4. Pipeline Therapeutics
5. Therapeutic Assessment
6. Plaque Psoriasis - DelveInsight's Analytical Perspective
7. Late Stage Products (Preregistration)
8. ARQ-151: Arcutis Biotherapeutics
9. Mid Stage Products (Phase II)
10. ABY-035: Affibody
11. Early Stage Products (Phase I)
12. CT303: GC Cell
13. Preclinical and Discovery Stage Products
14. Drug name: Company name
15. Inactive Products
16. Plaque Psoriasis Key Companies
17. Plaque Psoriasis Key Products
18. Plaque Psoriasis- Unmet Needs
19. Plaque Psoriasis- Market Drivers and Barriers
20. Plaque Psoriasis- Future Perspectives and Conclusion
21. Plaque Psoriasis Analyst Views
22. Plaque Psoriasis Key Companies
23. Appendix

Got Queries? Find out the related information on Plaque Psoriasis Mergers and acquisitions, Plaque Psoriasis Licensing Activities @ Plaque Psoriasis Emerging Drugs, and Recent Trends- https://www.delveinsight.com/sample-request/plaque-psoriasis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: info@delveinsight.com
Phone: 9193216187
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com

This release was published on openPR.